Race Oncology Ltd. (AU:RAC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd has appointed Dr. Megan Baldwin as an Independent Non-Executive Director, bringing over 25 years of experience in biotechnology and cancer therapy development. Dr. Baldwin, known for her leadership at Opthea Limited, is expected to leverage her extensive expertise in therapeutic drug development and corporate governance to drive Race’s future growth and success. This strategic move aligns with Race’s ongoing efforts to advance its lead asset, bisantrene, in addressing unmet needs in oncology treatment.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.